dc.contributor.author | Newton, G | |
dc.contributor.author | Schneider, M | |
dc.contributor.other | Chapman, K | |
dc.contributor.other | Aqil, R | |
dc.contributor.other | Jarvis, A | |
dc.coverage.spatial | International | |
dc.date.accessioned | 2020-08-19T09:50:04Z | |
dc.date.issued | 2020-06-11 | |
dc.identifier | GB2019053429W | |
dc.identifier | WO2020115481 | |
dc.identifier.citation | 2020 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3983 | |
dc.description.abstract | This invention relates to compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these compounds, for example in a method of treatmentof cardiac conditions.In particular, the present invention relates to compounds of formula (I): | |
dc.language | eng | |
dc.language.iso | eng | |
dc.subject | Kinase | |
dc.subject | Cardiovascular | |
dc.title | MAP4K4 Inhibitors | |
dc.type | Patent | |
rioxxterms.licenseref.startdate | 2020-06-11 | |
rioxxterms.type | Other | |
pubs.filed-date | 2018-12-05 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3 | |
pubs.patent-status | PCT | |
pubs.publication-status | Published | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicinal Chemistry 3 | |
dc.contributor.icrauthor | Newton, Gary | |